Rafael Blesa - Sant Pau Memory Unit - Alzheimer Research - Barcelona

Rafael Blesa

Rafael Blesa GonzalezDr. Rafael Blesa obtained his medical degree from the Universitat Autònoma de Barcelona in 1975 and specialized in Neurology at Hospital de la Santa Creu i Sant Pau.

After completing his Ph.D. in Medicine at the Universitat de Barcelona (1989) he worked at the National Institute of Health in Bethesda, Maryland (USA) as an associate researcher in experimental therapies. He returned to Barcelona in 1993 where he directed the Alzheimer and Other Cognitive Disorders Unit at Hospital Clínic for 10 years. Since 2003, Dr Blesa has been the Director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

Dr. Rafael Blesa is the author of more than 30 book chapters and more than 170 scientific articles published in high impact national and international journals, and he has been the principal investigator of over 70 research projects and pharmacological studies in the field of Alzheimer’s disease. He is a member of prestigious medical and scientific societies that have awarded his scientific contributions in numerous occasions.

In his professional trajectory, he has combined clinical and research tasks with teaching activities as an associate professor of Neurology at Universitat de Barcelona and Universitat Autònoma de Barcelona, and he has directed and supervised numerous doctoral theses.

Currently, besides directing the Neurology Department, Dr. Rafael Blesa is the principal investigator of the advanced therapies research line within the Memory Unit.


Recent Publications

  1. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Dekker, AD et al. J. Alzheimers Dis. 2018

  2. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL et al. Neurobiol. Aging 2018

  3. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. Broce, I et al. PLoS Med. 2018

  4. Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A et al. Oncotarget 2017

  5. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Colom-Cadena, M et al. Brain 2017

  6. Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Verheijen, J et al. Neurobiol. Aging 2018

  7. Cortical microstructural changes along the Alzheimer's disease continuum. Montal, V et al. Alzheimers Dement 2018

  8. Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Dols-Icardo, O et al. J. Neurol. Neurosurg. Psychiatry 2018

  9. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Sims, R et al. Nat. Genet. 2017

  10. The pitfalls of biomarker-based classification schemes. Illán-Gala, I et al. Alzheimers Dement 2017

  11. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Alcolea, D et al. Neurology 2017

  12. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Sala, I et al. J. Alzheimers Dis. 2017

  13. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Carmona-Iragui, M et al. Alzheimers Dement 2017

  14. Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. De Roeck, A et al. Acta Neuropathol. 2017

  15. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Dekker, AD et al. Alzheimers Dement (Amst) 2017

Search PubMed